BioSpace Movers & Shakers, Oct. 23
AVEO oncology – David Crist has been named Vice President of Sales at AVEO Oncology. He will be responsible for building AVEO’s field force to anticipate the potential approval and launch of tivozanib, the company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), for the treatment of relapsed or refractory renal cell carcinoma. During his career, Crist has held oncology-oriented sales roles at various pharmaceutical companies, including MGI (Molecular Genetics, Inc.), Eisai, Sanofi Genzyme, GlaxoSmithKline and ARIAD Pharmaceuticals.
Topas Therapeutics – The German Topas Therapeutics GmbH has appointed Klaus Martin as its new CEO. He replaces Timm Jesson, who has resigned for personal reasons. Martin joins Topas from Apobiologix of Toronto, the biotechnology division of Apotex, where he served as president since 2018. Previously he was Scientific Director of Polpharma Biologics, the biologics division of Polpharma SA. Before that he worked at Sandoz Biopharmaceuticals. both in Germany and Austria, most recently as Global Head Business Development & Licensing (BD & L) and Portfolio Management.
HepaRegeniX GmbH – David Shapiro is moving to HepaRegeniX in Germany as Senior Medical Advisor. Shapiro was most recently Chief Medical Officer and Head of Research and Development at Intercept Pharmaceuticals. Previously, he was CMO of Idun Pharmaceuticals. He was also previously President of the Scripps Clinic’s Scripps Medical Research Center.
Hookipa Pharma – Jean-Charles Soria has been appointed to the board of Hookipa Pharma Inc. Soria is Professor of Medicine and Medical Oncology at the University of Paris-Saclay and currently serves as General Director of the Gustave Roussy Cancer Center.
Centogens – CEO and founder Arndt Rolfs will step down. Andrin Oswald will take over management of the company on December 1st. Rolfs has agreed to act as a consultant during the transition period. Oswald was most recently the delegate for COVID-19 vaccines and immunotherapies at the Federal Government of Switzerland. He was previously director of Life Science Industry Engagement and Partnerships for the Bill & Melinda Gates Foundation. Before founding, he was responsible for business integration at GlaxoSmithKline. Before joining GSK, Oswald held various management positions at Novartis for more than 10 years.
Mereo BioPharma – Christine Fox has been appointed Chief Financial Officer and Heidi Peterson has been appointed Senior Vice President, Regulatory Affairs at Mereo BioPharma in London. Fox replaces the interim CFO and the current Mereo board member Michael Wyzga, who will continue to serve on the Mereo board. Prior to joining Mereo, Fox was Group Financial Controller and Treasurer of Travelport, where she led a global financial operations team. Prior to Travelport, she worked for KPMG in the USA and Switzerland for more than 10 years. Peterson was previously Vice President, Regulatory Affairs at Kartos Therapeutics. Prior to Kartos, Petersen had a similar role at Immune Design. Petersen was previously Vice President, Regulatory Affairs and Quality at BN-Immunotherapeutics.
Montage life sciences – Gina Consylman has been appointed to the board of directors of Bay Area-based Assembly Biosciences. Consylman will serve on the Assembly’s Audit Committee. Consylman is the Senior Vice President and CFO at Ironwood Pharmaceuticals. Consylman began her career at Ernst & Young LLP and has held financial leadership positions at a number of healthcare and technology companies.
Precigen, Inc. – Gaurav Vij has been named director of business development for Precigen, Inc. Vij will be responsible for accelerating strategic business development activities in Precigen’s platform and pipeline programs, including identifying and building new strategic partnerships to rapidly advance core resources. Vij joins Precigen from Gilead Sciences where he led efforts to successfully close several oncology transactions of high impact and value to the Gilead pipeline. Prior to Gilead, Vij worked in corporate development at Amgen and Shire Pharmaceuticals.
Lyndra Therapeutics – George Eldridge has been named CFO of Lynda Therapeutics. Eldridge will lead strategic global finance operations, including potential finance management, investor relations, mergers and acquisitions, and grow the company’s presence on Wall Street. Eldridge held CFO positions in various life science companies, most recently at Proteon Therapeutics, Inc. and previously at Targanta Therapeutics Corporation, Therion Biologics Corporation and Curis, Inc.
swim – Andrew N. Alexander joins Inotiv (Bioanalytical Systems, Inc.) as vice president of pharmacology and toxicology. Before joining Inotiv, Alexander founded Scientific Business Advisors, who advised companies in the fields of biopharmaceuticals, veterinary medicine and medical devices on scientific and regulatory issues.
Conversion Labs – Former White House doctor and US Navy counteradministrator Connie Mariano has been appointed to the Conversion Labs board of directors. She served in the White House as a doctor for three seated presidents for nine years. After leaving the White House, Dr. Mariano consulted on the Mayo Clinic’s Executive Health program and later founded the Center for Executive Medicine, a concierge doctor’s office.
Orchard Therapeutics – CEO Bobby Gaspar was appointed to the Board of Directors of the Alliance for Regenerative Medicine (ARM) in 2021. Working with the Executive Committee and Board of Directors, Gaspar will provide guidance to support the formation and implementation of ARM’s strategic priorities and focuses for the coming year.
TriSalus – Trevor McCaw has been named Chief Commercial Officer of TriSalus Life Sciences, a new role for the company. McCaw, most recently President and CCO of Clerio Vision, will play a pivotal role in integrating the company’s therapeutics and innovative drug delivery systems. In addition to his work at Clerio Vision, McCaw served as President and COO of Blueprint Clinical. McCaw founded Aegis Medical Innovations in Vancouver and oversaw the fundraising, surgery, R&D, and clinical trials of an implantable cardiovascular stroke prevention device licensed by the Mayo Clinic.